Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches
Executive Summary
After DEA scheduling, Reyvow will be available at pharmacies soon with a list price of $640 for eight tablets. Allergan confirmed that its drug is at pharmacies and prescriptions are being filled.
You may also be interested in...
Biohaven’s Q3 Nurtec ODT Sales Indicate Gains Across Multiple Launch Parameters
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
AbbVie Ready To Leverage Migraine Franchise In Crowded Market
The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.
Biohaven Pursues Best-In-Class Sales With Nurtec ODT’s Migraine Prevention Approval
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.